article thumbnail

First FDA pregnancy-approved Pertussis vaccine to protect newborns

European Pharmaceutical Review

The FDA initially approved Boostrix in 2005 as a vaccine to protect against Tdap in patients from 10 years old to 18. Side effect data related to those given the non-US variation during pregnancy was consistent with data for individuals who were given the non-US formulation post labour.

FDA 105
article thumbnail

Aiming for ‘Magic Bullets’ in Medicine: Are We Shooting Ourselves in the Foot?

Clarivate

A ‘magic bullet’ medicine that can cure a disease quickly and completely, [1] without deleterious side effects. [2] 6] As many pathogenetic targets have multiple physiological functions, highly specific ‘magic bullets’ may impact multiple cellular pathways simultaneously, causing unintended side effects.7 Chin J Cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

One aspect that is extremely promising about radiopharmaceutical therapeutics is that they do not give a patient the side effects that are commonly experienced with chemotherapy. Barrett at the Center for Gamma Ray Imaging.

article thumbnail

Gulf War Illness: How can disease modelling aid the search for a cure?

pharmaphorum

By introducing various drugs into the model, and adjusting their dosages, the model was able to demonstrate which drugs work best together, map potential side effects and drug interactions, and predict the efficacy of therapies. He served as Director of the Lowe Family Genomics Core at the Johns Hopkins University from 2005-15.

article thumbnail

Nanotechnology: A Massive Impact at the Molecular Level

Celeritas

They only partially impact the target areas and have damaging side effects in adjacent regions. Gold nanowires further positively impact key organ transplant functions – synapse formation and stem cell differentiation – all without using growth factors, which cause negative side effects. 16 August 2005).

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience.

article thumbnail

Beating the Big C

Pharmaceutical Technology

It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler. We’re on the right path.”